ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
Transgene Biotek submitted its quarterly shareholding pattern for the period ending December 2016. The company noted that certain promoter shares remain in physical form pending listing approval.
Transgene Biotek Ltd submitted a nil compliance report under Regulation 57 of SEBI LODR for the quarter ended March 31, 2026. The company confirmed it has no outstanding non-convertible securities for which interest, dividend, or principal is payable. This is a routine regulatory filing with no material financial impact.
Transgene Biotek Ltd submitted a NIL compliance report under Regulation 57(5) of SEBI LODR. The company confirmed it has no outstanding non-convertible securities and consequently no interest or principal payment obligations for the quarter ended March 31, 2026.